HIV-1 Infection: LANOGRAV is indicated for the treatment of HIV-1 infection in adults aged 18 years and older. It is not recommended for use in patients younger than 18 years of age.
Instructions:
Dosage: One tablet taken orally, once daily, without regard to food.
Administration: May be taken with or without food.
Precautions:
Not suitable for patients with renal impairment (creatinine clearance < 80 ml/min).
Rifampicin decreases the blood levels of dolutegravir; a supplementary dose of dolutegravir may be needed.
Isoniazid concentration is increased by dolutegravir.
Overdose: Monitor for evidence of toxicity and apply supportive treatment as necessary.
Malaysia
